

# The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma

## SUPPLEMENTARY MATERIALS

Supplementary Table 1: 3 selected oligos for sh-METTL3 lentivirus construct

No	Start	Oli Oligo Sequence go Type
Sh-M3-1		
	Top Strand	5'- CACCGCTGCACTTCAGACGAATTATCGAAATAATTCGTCTGAAGTGCAGC -3'
	Bottom Strand	5'- AAAAGCTGCACTTCAGACGAATTATTCGATAATTCGTCTGAAGTGCAGC -3'
	ds Oligo	5'- CACCGCTGCACTTCAGACGAATTATCGAAATAATTCGTCTGAAGTGCAGC -3'
		3'- CGACGTGAAGTCTGCTTAATAGCTTTATTAAGCAGACTTCACGTGCGAAAA -5'
Sh-M3-2		
	Top Strand	5'- CACCGGATACCTGCAAGTATGTTACGAAATGAACATACTTGCAGGTATCC -3'
	Bottom Strand	5'- AAAAGGATACCTGCAAGTATGTTATTCGTGAACATACTTGCAGGTATCC -3'
	ds Oligo	5'- CACCGGATACCTGCAAGTATGTTACGAAATGAACATACTTGCAGGTATCC -3'
		3'- CCTATGGACGTTTCATACAAGTGCTTACTTGTATGAACGTCCATAGGAAAA -5'
Sh-M3-3		
	Top Strand	5'- CACCGCTCAACATACCCGTAACGAAATGTAGTACGGGTATGTTGAGC -3'
	Bottom Strand	5'- AAAAGCTCAACATACCCGTAACATTCGTGTAGTACGGGTATGTTGAGC -3'
	ds Oligo	5'- CACCGCTCAACATACCCGTAACGAAATGTAGTACGGGTATGTTGAGC -3'
		3'- CGAGTTGTATGGGCATGATGTGCTTACATCATGCCATACAACCTCGAAAA -5'

Mettl3 : XM\_006720206.1 [http://www.ncbi.nlm.nih.gov/nuccore/XM\\_006720206.1](http://www.ncbi.nlm.nih.gov/nuccore/XM_006720206.1) (The enzyme loci were marked by yellow).

GCTAGCATGAAAGCCAGTGATGCTGATCGACCCTGTCGCAAGCTGCACTTCAGACGAATTATCAATAAACACA CTG.

ATGAGTCTTTAGGTGACTGCTCTTTCCTTAATACATGTTCCACATGGATACCTGCAAGTATGTTCACTA TGAAATTGATGCTTGCATGGATTCTGAGGCCCTGGCAGCAAAGACCACACGCCAAGCCAGGAGCTTGCT CTTACACAGAGTGTGCGGAGGTGATTCCAGTGCAGACCGACTCTTCCCACCTCAGTGGATCTGTTGTGATA TCCGCTACCTGGACGTCAGTATCTTGGGCAAGTTTGCAGTTGTGATGGCTGACCCACCCTGGGATATTCA CATGGAAGTGCCTATGGGACCCTGACAGATGATGAGATGCGCAGGCTCAACATACCCGTAACAGGAT GATGGCTTTCTCTTCTCTGGGTACAGGCAGGGCCATGGAGTTGGGGAGAGAATGTCTAAACCTCTGGG GGTATGAACGGGTAGATGAAATTATTTGGGTGAAGACAAATCAACTGCAACGCATCATTCGGACAGGCCG TACAGGTCAGTGGTTGAACCATGGGAAGGAACACTGCTTGGTTGGTGTCAAAGGAAATCCCAAGGCTTC AACCAGGGTCTGGATTGTGATGTGATCGTAGCTGAGGTTTCGTTCCACCAGTCATAAACCAGATGAAATCT ATGGCATGATTGAAAGACTATCTCCTGGCACTCGCAAGATTGAGTTATTTGGACGACCACACAATGTGCA ACCCAACTGGATCACCTTGGAAACCAACTGGATGGGATCCACCTACTAGACCCAGATGTGGTTGCACGG TTCAAGCAAAGGTACCCAGATGGTATCATCTCTAAACCTAAGAATTTATAGGGCGCGCC.

**Supplementary Table 2: Characteristics of the 145 RCC patients involved in this study**

See Supplementary File 1